Diabetogen completes first round financing

Guest Contributor
February 11, 2002

Diabetogen Biosciences Inc, London ON, has raised $7.8 million in first-round equity investment to move its technology platform for the treatment of autoimmune diseases towards clinical trials. The firm is currently working towards treatment for Type I diabetes. The financing was provided by the Business Development Bank of Canada Venture Capital Division, VentureLink Group of Funds Inc, StrategicNova Canadian Technology Fund, Eastern Technology Seed Investment Fund and Dynex Capital Inc. Diabetogen has already established strategic partnerships with Abgenix Inc and others, and is seeking additional partnerships….

Westport completes $47.9-million share offering

Westport Innovations Inc, Vancouver, has raised net proceeds of $47.9 million through share offering of 6,836,000 shares at $7 each. The bought-deal equity financing includes an underwriters option of nearly 2 million additional shares. Westport develops technology enabling diesel engines to operate on natural gas. Through a joint venture — Cummins Westport — the firm sells three lines of alternative fuel, sparking-ignited engines designed by Cummins for use in transit, shuttle and school buses….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.